Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Three Solid Stocks to Buy for Dividend Income and Value
The appeal of dividend-paying equities often gets overshadowed by the excitement surrounding growth stocks. Yet growth investments frequently come with higher volatility and inflated valuations that leave them vulnerable to significant pullbacks. By contrast, dividend-yielding companies typically demonstrate financial stability and mature business models. Companies don’t commit to dividend payments lightly—cutting or suspending dividends sends a red flag to the market. This is why income-focused investors should explore these stocks to buy as core holdings for building reliable portfolio returns.
Pfizer: Pharma Giant Navigating Strategic Transformation
Pharmaceutical leader Pfizer (NYSE: PFE) currently offers an attractive dividend yield of around 6.7%, making it one of the more generous payouts available today. The company faced headwinds as its COVID-19 vaccine and Paxlovid treatment lost market relevance, and several key drugs approached patent expiration. These challenges pressured stock valuations—which paradoxically boosted its yield for new investors.
However, management has been actively strengthening future prospects. The company secured a licensing partnership with YaoPharma for a GLP-1 drug candidate, positioning itself in the high-growth metabolic health space. Meanwhile, Pfizer’s enhanced oncology pipeline could deliver significant revenue drivers. While a full turnaround may extend beyond 2026, leadership has publicly committed to maintaining and growing dividends through this transition period. From a valuation perspective, Pfizer trades at a forward P/E of 8.7—below its five-year average of 9.7—offering reasonable entry pricing for value-conscious investors seeking current income.
Western Union: Legacy Company Embracing Digital Evolution
Western Union (NYSE: WU) presents an even more compelling dividend story, with a recent yield exceeding 10%. When accounting for aggressive share repurchases, total shareholder yield approaches 17%. Despite its 175-year history, the company has repeatedly reinvented itself, and its latest chapter involves exploring cryptocurrency infrastructure, including stablecoin technology and digital money transfer capabilities.
Recent operational results demonstrate underlying strength. Third-quarter revenue held steady while operating margins expanded to 20%, and the consumer services segment posted 49% year-over-year expansion. The stock appears reasonably priced at a forward P/E of 5.3, substantially below the five-year historical average of 7.3. While fintech evolution creates ongoing uncertainty requiring investor attention, the combination of current dividend yield and potential business modernization offers a compelling value proposition for income-focused portfolios.
Schwab U.S. Dividend Equity ETF: Diversified Approach to Dividend Investing
For investors preferring diversification, the Schwab U.S. Dividend Equity ETF (NYSEMKT: SCHD) provides an alternative to individual stock selection. This fund delivers a 3.8% dividend yield alongside a 10-year average annual return of 2.9%. The portfolio comprises 100 companies with at least one decade of consecutive dividend increases—ensuring exposure to financially disciplined businesses.
Recent top holdings include Lockheed Martin, Bristol-Myers Squibb, and Chevron, representing stability across aerospace, pharmaceuticals, and energy sectors. This ETF offers a balanced combination of recurring income distribution and potential capital appreciation, making it suitable for building a cornerstone position in a dividend-focused strategy.
Building Your Dividend Strategy
Income-producing stocks to buy should form a foundational component of long-term wealth building. The three options presented—whether individual pharmaceutical and financial services positions or a diversified equity fund—each offer mechanisms to generate steady returns while maintaining exposure to potential appreciation. Evaluate your risk tolerance, time horizon, and income requirements before selecting which approach aligns with your objectives.